PMID- 23149017
OWN - NLM
STAT- MEDLINE
DCOM- 20130830
LR  - 20130311
IS  - 1095-8320 (Electronic)
IS  - 1045-1056 (Linking)
VI  - 41
IP  - 2
DP  - 2013 Mar
TI  - Analyzing titers of antibodies against bacterial and viral antigens, and 
      bacterial toxoids in the intravenous immunoglobulins utilized in Taiwan.
PG  - 88-92
LID - S1045-1056(12)00173-X [pii]
LID - 10.1016/j.biologicals.2012.10.003 [doi]
AB  - Intravenous immunoglobulin (IVIG) manufactured from human plasma contains IgG as 
      the primary ingredient, and is used for indications such as immunodeficiency 
      syndrome. Available IVIGs in Taiwan are either manufactured from Taiwanese or 
      North American plasma. The effectiveness of the national immunization program of 
      Taiwan can be evaluated by analyzing and comparing IVIG antibody titers that are 
      induced through the corresponding vaccines (tetanus, diphtheria, and pertussis, 
      measles, rubella, hepatitis A, hepatitis B and varicella). Both enzyme-linked 
      immunosorbent assay (ELISA) and the in vitro neutralization test demonstrated 
      that all IVIGs provide adequate clinical protection against diphtheria and 
      tetanus toxins. ELISA results further revealed that plasma of Taiwanese subjects 
      contains higher levels of pertussis toxin and filamentous hemagglutinin 
      antibodies, when compared to foreign IVIGs. This may be related to the later 
      adoption of acellular pertussis vaccine in Taiwan. Antibodies titers against 
      measles, rubella, hepatitis A, and varicella-zoster virus were otherwise low. Low 
      titers of hepatitis B surface antigen antibodies are present in Taiwanese plasma 
      IVIG, indicating immune memory decline or loss. In conclusion, our results show 
      that Taiwanese IVIG contains varying titers of vaccine-induced antibodies, and 
      serves as a guide for future amendments to Taiwan's immunization program.
CI  - Copyright (c) 2013 The International Alliance for Biological Standardization. 
      Published by Elsevier Ltd. All rights reserved.
FAU - Wu, Chi-Yu
AU  - Wu CY
AD  - Section of Biologics & Advanced Therapeutic Product Analysis, Division of 
      Research and Analysis, Food and Drug Administration, Department of Health, 
      Executive Yuan, Taiwan, ROC.
FAU - Wang, Hsiu-Chi
AU  - Wang HC
FAU - Wang, Kun-Teng
AU  - Wang KT
FAU - Yang-Chih Shih, Daniel
AU  - Yang-Chih Shih D
FAU - Lo, Chi-Fang
AU  - Lo CF
FAU - Wang, Der-Yuan
AU  - Wang DY
LA  - eng
PT  - Journal Article
DEP - 20121111
PL  - England
TA  - Biologicals
JT  - Biologicals : journal of the International Association of Biological 
      Standardization
JID - 9004494
RN  - 0 (Antibodies)
RN  - 0 (Antigens, Bacterial)
RN  - 0 (Antigens, Viral)
RN  - 0 (Bacterial Vaccines)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Toxoids)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Antibodies/blood/*immunology
MH  - Antigens, Bacterial/*immunology
MH  - Antigens, Viral/*immunology
MH  - Bacterial Vaccines/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Immunization Programs/methods/standards
MH  - Immunoglobulins, Intravenous/*immunology
MH  - Taiwan
MH  - Toxoids/*immunology
MH  - Viral Vaccines/immunology
EDAT- 2012/11/15 06:00
MHDA- 2013/08/31 06:00
CRDT- 2012/11/15 06:00
PHST- 2012/05/09 00:00 [received]
PHST- 2012/09/20 00:00 [revised]
PHST- 2012/10/05 00:00 [accepted]
PHST- 2012/11/15 06:00 [entrez]
PHST- 2012/11/15 06:00 [pubmed]
PHST- 2013/08/31 06:00 [medline]
AID - S1045-1056(12)00173-X [pii]
AID - 10.1016/j.biologicals.2012.10.003 [doi]
PST - ppublish
SO  - Biologicals. 2013 Mar;41(2):88-92. doi: 10.1016/j.biologicals.2012.10.003. Epub 
      2012 Nov 11.